Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

[Repairing diabetic rats with bone defect by VEGF165 gene modified adipose-derived stem cells].

Wang HJ., Cai B., Zhao XY., Li SQ., Feng W., Liu JG.

Animal Study on Systemic / IV, published in Zhongguo Gu Shang (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Zhongguo Gu Shang (2017)
Country
China
Reported sample size
—
Source database
PubMed
PMID
29424176
DOI
10.3969/j.issn.1003-0034.2017.06.012
Citations
6

Abstract (original English)

Objective To explore repairing results of VEGF165 gene modified adipose-derived stem cells for diabetic rats with bone defect. Methods Seventy-eight male Wistar rats weighted 180 to 220 g were selected, 72 rats were established diabetic animal models by streptozotocin inducement method, blood glucose level was more than 16.7 mmol/L. Experimental animals were randomly divided into 5 groups, 6 rats in normal group and each 18 rats in other groups. VEGF165 gene modified adipose-derived stem cells were implanted into normal group with bone defect; single diabetic rats with bone defect were named as diabetic group;vascular endothelial growth factor implanted into single diabetic rats with bone defect named as growth factor group; adipose-derived stem cells implanted into diabetic rats with bone defect names as stem cell group; VEGF165 gene modified adipose-derived stem cells implanted diabetic rats with bone defect named as experimental group. After combination of VEGF165-ADSCs (5×106) cells combined with gel sponge, implanted into diabetic rats with bone defect. On the forth week, general form of defect repairing tissue were observed by optical microscopy;local density of micro-vessel were detected by immunohistochemistry method; content of Ca, P and ALP of repairing callus were detected by IRIS Intrepid XSP inductively coupled plasma emission spectrometer. Efficacy of the VEGF165-

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsBone and BonesDiabetes Mellitus, ExperimentalMaleNeovascularization, PhysiologicOsteogenesisRandom AllocationRatsRats, Sprague-Dawley

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research